Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Consumer-Focused Off-Label Promotion Seems Possible After Amarin Settlement

Executive Summary

Legal agreement with FDA allowing communication about off-label Vascepa use is not limited by audience, speaker or setting, attorneys say.


Related Content

Amarin Says REDUCE-IT Results Are Off Limits To Omega-3 Supplement Claims
Amarin Asks To Stifle Supplement Firms About Its Omega-3 Trial Results
How Should US FDA Navigate Thorny First Amendment Conundrums: Former Chief Counsels Offer Advice
Former US FDA Chief Counsels Offer Advice For Navigating Thorny First Amendment Conundrum
REDUCE-IT Will Test Risks Of Weakening Protection Of FDA-Labeled Claims
Advertising Enforcement: US FDA Content To Let Competitors 'Duke It Out,' Woodcock Says
Pharma-Related Probes Could Be Impacted By Departure Of US Attorneys
Patient-Centered Promotion? Marathon's Non-Launch Of Emflaza Illustrates Challenge Of New Era
First Amendment Does Not Block Off-Label Enforcement Actions, FDA Reiterates
Off-Label Promotion: 'Safe Harbor' Preferable To Expansive Free Speech Rulings


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts